🔎 Trials Near Me

Inicio › Obesidad › Carolina del Norte

Ensayos clínicos de Obesidad en Carolina del Norte

61 estudios sobre Obesidad buscan participantes en Carolina del Norte.

Ciudades en Carolina del Norte

Texto oficial del estudio (inglés)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

  • Medication Management /ID# 281965, Greensboro
  • Monroe Biomedical Research /ID# 282009, Monroe
  • Centricity Research - Morehead city /ID# 283264, Morehead City
  • y 2 más
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07752979

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

  • University of North Carolina at Chapel Hill, Chapel Hill
Reclutando
Edades de 18 a 75 · Todos los sexos · Actualizado el 29 sept 2026 · NCT06724406

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Medication Mgmnt, LLC_Grnsboro, Greensboro
  • Accellacare of Raleigh, Raleigh
  • Accellacare-Salisbury PMG Res, Salisbury
  • y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07720271

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • Medication Management, LLC, Greensboro
  • Accellacare - Wilmington, Wilmington
  • Jeffrey Coleman, OD, Wilmington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07595549

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • TMA Headlands, Wilmington
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 sept 2026 · NCT07837973

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

  • PharmQuest Life Sciences LLC, Greensboro
  • Piedmont Healthcare/Research, Statesville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07668414

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • UNC Children's Hospital, Chapel Hill
  • Duke Children's Primary Care, Durham
  • Lucas Research, Inc, Morehead City
ReclutandoFase 3
Edades de 6 a 17 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06672549

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

  • UNC Eastowne Medical Office, Chapel Hill
  • PharmQuest Life Sciences LLC, Greensboro
  • Accellacare and KDCILM, LLC, Wilmington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT07339423

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Coastal Research Institute - Fayetteville, Fayetteville
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937086

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Coastal Research Institute - Fayetteville, Fayetteville
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06937099

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  • Carolina Research Center, Shelby
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07153471

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • PharmQuest Life Sciences, LLC, Greensboro
  • West Clinical Research, Morehead City
  • Trial Management Associates - Wilmington - Floral Parkway, Wilmington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07282600

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Novant Health Heart and Vascular Institute, Charlotte
  • Velocity Clinical Research - Durham, Durham
  • Moses H Cone Memorial Hospital, Greensboro
  • y 7 más
ReclutandoFase 3
Edades de 45 a 99 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Monroe Biomedical Research, Monroe
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07321886

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Monroe
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07784270

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Medication Management, Greensboro
  • Monroe Biomedical Research, Monroe
  • Lucas Research, Inc, Morehead City
  • y 1 más
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 22 sept 2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • University of North Carolina Medical Center, Chapel Hill
  • Medication Management, Greensboro
  • Carteret Medical Group, Morehead City
  • y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07392190

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Asheville Cardiology Associates, Asheville
  • Duke University Health System, Durham
  • Ima Clinical Research - Lenoir, Lenoir
  • y 2 más
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 16 sept 2026 · NCT07037459

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Charlotte
  • AURORA-2 Clinical Site, Durham
  • AURORA-2 Clinical Site, Greenville
  • y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Charlotte
  • AURORA-1 Clinical Site, Greenville
  • AURORA-1 Clinical Site, Morehead City
  • y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743463

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • Centricity Research Morehead City Multispeciality, Morehead City
  • Wake Forest University Health Sciences, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Lucas Research, Inc., Morehead City
  • Shelby Clinical Research, Shelby
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 sept 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Charlotte
  • ACCOMPLISH-2 Research Site, Durham
  • ACCOMPLISH-2 Research Site, Fayetteville
  • y 2 más
ReclutandoFase 3Se aceptan voluntarios sanos
Edades de 18 a 79 · Todos los sexos · Actualizado el 11 sept 2026 · NCT07654374

Tirzepatide in Obesity-Driven Endometrial Cancer

  • Lineberger Comprehensive Cancer Center, Chapel Hill
ReclutandoFase 1 temprana
Edades de 18 en adelante · Mujeres · Actualizado el 11 sept 2026 · NCT07065552

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Medication Management, Greensboro
  • Monroe Biomedical Research, Monroe
  • Lucas Research, Inc, Morehead City
  • y 1 más
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 sept 2026 · NCT06143956

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

  • PharmQuest, Greensboro
  • KDCILM, LLC & Accellacare US, Inc., Wilmington
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07745504

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • Revival Research Institute, LLC, Cary
  • Onsite Clinical Solutions - Huntersville, Huntersville
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Greensboro
  • Kailera Clinical Site, Monroe
  • Kailera Clinical Site, Morehead City
  • y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284901

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Morehead City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Accellacare of Hickory, Hickory
  • Carolina Research Center Inc, Shelby
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  • West Clinical Research, Morehead City
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 3 sept 2026 · NCT07684144

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

  • Kailera Clinical Site, Morehead City
  • Kailera Clinical Site, Morrisville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT07284979

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Centricity Research Morehead City Specialty, Morehead City
  • Accellacare of Raleigh, Raleigh
  • Accellacare Research of Wilmington, Wilmington
ReclutandoFase 3
Edades de 18 a 99 · Todos los sexos · Actualizado el 27 ago 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Statesville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT07784725

Using Tailored mHealth Strategies to Promote Weight Management Among Adolescent and Young Adult Cancer Survivors

  • University of North Carolina at Chapel Hill, Chapel Hill
Reclutando
Edades de 18 a 39 · Todos los sexos · Actualizado el 24 ago 2026 · NCT06848491

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Levine Children's Hospital, Charlotte
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Peak Clinical Trials, Apex
  • Hawthorne Health NC, Concord
  • Duke University, Durham
  • y 5 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT07567001

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  • Piedmont Healthcare/Research, Statesville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Charlotte
  • ACCOMPLISH-1 Research Site, Durham
  • ACCOMPLISH-1 Research Site, Fayetteville
  • y 3 más
ReclutandoFase 3
Edades de 18 a 79 · Todos los sexos · Actualizado el 10 ago 2026 · NCT07654361

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.